ioneer IONR 深 沪
等待开盘 11-06 09:30:00 美东时间
2.55
-0.130
-4.85%
华盛通- 最 高2.745
- 今 开2.74
- 成交量 11.85万股
- 最 低 2.535
- 昨 收 2.68
- 总市值 1.93亿
- 52周最高 6.5335
- 市盈率 静 --
- 换手率 0.16%
- 52周最低 2.5268
- 委 比 88.38%
- 总股本 7582.78万
- 历史最高 24.00
- 量 比 2.07
- 振 幅 7.84%
- 历史最低 2.30
- 每 手 1
- 风险率 0.79%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Kura Oncology granted inducement stock options to three new employees under its 2023 Inducement Option Plan. The options, totaling 55,500 shares with an exercise price of $9.79 per share, vest over four years, with 25% vesting after one year and the remainder vesting monthly over the next 36 months. The grant aligns with Nasdaq Listing Rule 5635(c)(4).
今天 12:30
InflaRx Announces Publication of Phase 1 Data Demonstrating Favorable Safety and Pharmacokinetic/Pharmacodynamic Profile of Izicopan
InflaRx announced positive Phase 1 clinical data for izicopan, an oral C5a receptor inhibitor, showing rapid and sustained inhibition of C5a/C5aR1 signaling, favorable pharmacokinetics, and strong safety profile across doses. The study, conducted in 86 healthy participants, supports Phase 2 development for immune-inflammatory diseases.
今天 12:30
Treace Announces First Surgical Cases with the Tailorplasty™ MIS Tailor’s Bunion Correction System
Treace Medical Concepts announced the successful launch of its Tailorplasty™ MIS Tailor’s Bunion Correction System, addressing fifth metatarsal deformities, or tailor’s bunions, affecting 5-10% of adults. The system offers a minimally invasive solution with instrument-guided correction and a unique fixation implant, improving surgical accuracy and stability. Designed to simplify challenging procedures, Tailorplasty™ aims to expand Treace’s market...
今天 12:04
LETTER TO SHAREHOLDERS
Devon Energy has achieved significant milestones since its Coterra combination, including a comprehensive portfolio review, strategic divestitures, and major acquisitions in the Permian Basin. The company emphasizes operational excellence, technology innovation, and a disciplined approach to capital allocation. Key initiatives include expanding in the Permian Basin, optimizing complementary assets, and enhancing shareholder returns through increa...
11-05 21:11
Aprea Therapeutics to Present at the Guggenheim 3rd Annual Healthcare Innovation Conference
Aprea Therapeutics' CEO, Oren Gilad, will participate in a fireside chat at Guggenheim’s 3rd Annual Healthcare Innovation Conference on November 9, 2026, at 10:00 am ET in Boston. Interested investors can join via the provided webcast link. Aprea, a precision medicine oncology company, focuses on developing targeted therapies for biomarker-defined cancers, with lead programs APR-1051 and ATRN-119 in clinical development. For more information, vis...
11-05 21:05
Arteris Surpasses 1,000 Customer Design Starts, Highlighting the Evolution of Semiconductor Design
Arteris, Inc. has achieved a milestone of 1,000 customer silicon design starts, highlighting its leadership in enabling advanced semiconductor architectures for AI infrastructure, edge devices, and physical AI applications. The company's interconnect IP solutions address growing design complexity, supporting a wide range of silicon architectures from microcontrollers to multi-die SoCs. A new report reveals key trends, including the exponential gr...
11-05 14:00
AIR Submits Premarket Tobacco Product Application for Crown Switch Rechargeable Pod Vape Platform
AIR Global PLC submitted a PMTA to the FDA for its Crown Switch vape platform, aiming to establish a science-driven presence in the U.S. vaping market. The application includes extensive scientific evidence on product quality, consumer behavior, and health impacts. Crown Switch uses Greentank’s Quantum Vape technology and is designed to reduce leakage and prevent youth access. AIR believes the product could provide adult smokers with a safer alte...
11-05 13:00
Baird Medical and Alpmed Announce FDA 510(k) and EU CE Submissions for Irreversible Electroporation (IRE) System
Baird Medical and its partner Alpmed submitted a 510(k) application to the FDA and a CE application for an irreversible electroporation (IRE) system in Q4 2026. The IRE system, designed for soft tissue ablation, uses high-voltage electrical pulses to treat tumors near sensitive structures. Baird Medical leads global regulatory interactions and holds worldwide commercial rights. The companies aim for FDA clearance and EU CE marking in 2027. This m...
11-05 13:00
LGI Homes, Inc. Reports October 2026 Home Closings
LGI Homes, Inc. reported closing 297 homes in October 2026, including 9 single-family rental homes. As of October 31, 2026, the company had 151 active selling communities. Headquartered in The Woodlands, Texas, LGI Homes operates in 36 markets across 21 states and has closed over 80,000 homes since 2003. The company is known for its quality construction, customer service, and workplace awards, including being named to Newsweek’s list of the World...
11-04 22:23
Processa Pharmaceuticals Announces Key Leadership Appointments
Processa Pharmaceuticals announced key leadership appointments to support its growth, including Gregory Flesher as Chief Operating Officer, Craig Coburn, Ph.D., as Executive Vice President, Head of Research, Ashley Hall, J.D., as Executive Vice President, Development, and Michael P. Cruse as Executive Vice President, Business Operations. These appointments follow the company's July 2026 acquisition of Vidya Therapeutics. Processa is advancing its...
11-04 13:00
